<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02454556</url>
  </required_header>
  <id_info>
    <org_study_id>GEMFOL001</org_study_id>
    <nct_id>NCT02454556</nct_id>
  </id_info>
  <brief_title>A Randomized, Multicentre, Open Label, Evaluator Blinded Study to Evaluate Safety and Efficacy of Folitime® of Gemabiotech S.A., Versus Gonal-f ® of Merck Serono, in Patients With Infertility Undergoing ART</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gema Biotech S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>QUID Quality in Drugs and Devices Latin American Consulting SRL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gema Biotech S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, Phase 3, randomized, two arms, multicenter, prospective, experimental&#xD;
      study of Folitime® (a new biosimilar formulation of r-hFSH, follitropin alfa) versus the&#xD;
      original one (Gonal-f ®).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Follitropin alfa is a human follicle stimulating hormone (FSH) preparation of recombinant DNA&#xD;
      origin, which consists of two non-covalently linked, nonidentical glycoproteins designated as&#xD;
      the alfa- and beta-subunits. Similar to other glycoprotein hormones, FSH has a high degree of&#xD;
      heterogeneity due to differences in the amount and/or composition of the carbohydrate&#xD;
      residues, particularly sialic acid. FSH, the active component of r-hFSH is the most important&#xD;
      hormone responsible for follicular recruitment and development. In order to obtain final&#xD;
      maturation of the follicle and ovulation in the absence of an endogenous LH surge, human&#xD;
      chorionic gonadotropin (hCG) must be given following the administration of r-hFSH when&#xD;
      monitoring of the patient indicates that sufficient follicular development has occurred.&#xD;
&#xD;
      Secondary endpoints to be measured by the study are&#xD;
&#xD;
      Efficacy&#xD;
&#xD;
        -  Total dose of r-hFSH required,&#xD;
&#xD;
        -  Number of days of r-hFSH stimulation&#xD;
&#xD;
        -  Percentage of patients with need to increase or lower the dose of r-hFSH,&#xD;
&#xD;
        -  Number of treatment cycle cancellations and their reason&#xD;
&#xD;
        -  Fertilization rate&#xD;
&#xD;
        -  Number of fertilized oocytes&#xD;
&#xD;
        -  Number of good quality embryos&#xD;
&#xD;
        -  Number of embryos transferred&#xD;
&#xD;
        -  Implantation Rate&#xD;
&#xD;
        -  Biochemical pregnancy&#xD;
&#xD;
        -  Clinical pregnancy 10 weeks post embryo transfer&#xD;
&#xD;
        -  Pregnancy outcome&#xD;
&#xD;
      Safety&#xD;
&#xD;
      Incidence of&#xD;
&#xD;
        -  OHSS (and its severity)&#xD;
&#xD;
        -  Local reactions (pain, bruising, redness, itching, swelling)&#xD;
&#xD;
        -  Systemic drug adverse events&#xD;
&#xD;
      Tolerability&#xD;
&#xD;
        -  Frequency of patients who withdraw the study drug due to lack of tolerance&#xD;
&#xD;
        -  Frequency of patients who withdraw the study drug treatment due to any reason&#xD;
&#xD;
        -  Patient Reported Pain: measured by a Patients Visual Analog Scale (VAS)&#xD;
&#xD;
      Immunogenicity Measurement of possible antibodies against exogenous r-hFSH will be evaluated.&#xD;
      Pharmacodynamics&#xD;
&#xD;
        -  Number and size distribution of follicles during treatment&#xD;
&#xD;
        -  Number and size distribution of follicles at the day of ovulation induction (uHCG)&#xD;
&#xD;
        -  Number of follicles &gt;14 mm on the day of hCG injection.&#xD;
&#xD;
        -  Hormone parameters: serum levels of estradiol, luteinizing hormone and progesterone on&#xD;
           the day of hCG injection&#xD;
&#xD;
        -  Metaphase II oocytes;&#xD;
&#xD;
        -  Number of good quality oocytes&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of oocytes retrieved</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>FOLITIME®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapy will be initiated in the early follicular phase (cycle day 2 or 3) subcutaneously at a dose of 225 IU per day, until sufficient follicular development is attained.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gonal-F®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Therapy will be initiated in the early follicular phase (cycle day 2 or 3) subcutaneously at a dose of 225 IU per day, until sufficient follicular development is attained.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLITIME®</intervention_name>
    <arm_group_label>FOLITIME®</arm_group_label>
    <other_name>Follitropin alfa (r-hFSH)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonal-F®</intervention_name>
    <arm_group_label>Gonal-F®</arm_group_label>
    <other_name>Follitropin alfa (r-hFSH)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 38 years of age&#xD;
&#xD;
          -  Indication for controlled ovarian stimulation and IVF or intracytoplasmic sperm&#xD;
             injection (ICSI)&#xD;
&#xD;
          -  Regular menstrual cycles (25-35 days)&#xD;
&#xD;
          -  History of a maximum of two fresh cycle treatments in the present series of assisted&#xD;
             reproductive technologies (ART) at the day of first screening (thawed cycles are not&#xD;
             subject to that criteria)&#xD;
&#xD;
          -  Body mass index (BMI) ≥18 and ≤32 kg/m2&#xD;
&#xD;
          -  Basal FSH &lt;10 IU/L (cycle day 2-5)&#xD;
&#xD;
          -  Antral follicle count (AFC) ≥8 to ≤18 follicles with a diameter of &lt;10mm (sum of both&#xD;
             ovaries) as measured on ultrasound (US) in the early follicular phase (day 1 of the&#xD;
             stimulation cycle or of the last cycle previous to the treatment)&#xD;
&#xD;
          -  Documented history of infertility due to any of the following factors: tubal factor,&#xD;
             male factor, unexplained infertility&#xD;
&#xD;
          -  Presence of both ovaries by ultrasonography and normal uterine cavity or abnormal&#xD;
             uterine cavity without clinical significance according to the investigator's opinion&#xD;
             (confirmed by hysterosalpingography, saline infusion sonography or hysteroscopy within&#xD;
             12 months before randomization) and normal uterine cavity by transvaginal ultrasound&#xD;
             within 3 months of treatment&#xD;
&#xD;
          -  Male partner with semen analysis that is at least adequate for ICSI within 6 months&#xD;
             prior to patient beginning down-regulation (invasive or surgical sperm retrieval,&#xD;
             donor and/or cryopreserved sperm may be used)&#xD;
&#xD;
          -  Willingness to participate in the study and to comply with the study protocol&#xD;
&#xD;
          -  Signed informed consent prior to screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of pregnancy&#xD;
&#xD;
          -  History of or active polycystic ovary syndrome (PCOS)&#xD;
&#xD;
          -  AFC &gt;18 follicles with a diameter of &lt;10 mm (both ovaries combined) as measured on US&#xD;
             in the early follicular phase (menstrual cycle day 2-5) or during&#xD;
&#xD;
          -  History of &gt;2 unsuccessful fresh ART retrieval cycles&#xD;
&#xD;
          -  History of poor response to gonadotropin treatment (defined as fewer than 5 oocytes&#xD;
             retrieved in a previous attempt)&#xD;
&#xD;
          -  Any hormonal treatment within 1 month before the start of the FSH treatment, with the&#xD;
             exception of levothyroxine)&#xD;
&#xD;
          -  Egg donor&#xD;
&#xD;
          -  Intrauterine leiomyomas ≥5 cm or otherwise clinically relevant pathology that could&#xD;
             impair embryo implantation or pregnancy continuation&#xD;
&#xD;
          -  Previous history of OHSS&#xD;
&#xD;
          -  Ovarian cyst or enlargement of undetermined origin&#xD;
&#xD;
          -  History of recurrent spontaneous abortion (3 or more, even when unexplained)&#xD;
&#xD;
          -  Presence of endometriosis or hydrosalpinx&#xD;
&#xD;
          -  Neoplasia, including tumors of the hypothalamus and pituitary gland&#xD;
&#xD;
          -  Abnormal genital bleeding of undetermined origin&#xD;
&#xD;
          -  History of extrauterine pregnancy in the previous 3 months&#xD;
&#xD;
          -  Sex hormone dependent tumors of the reproductive tract and accessory organs.&#xD;
&#xD;
          -  Uncontrolled thyroid or adrenal dysfunction or presence of uncontrolled endocrine&#xD;
             disorder&#xD;
&#xD;
          -  Known allergy or hypersensitivity to FSH preparations or one of their excipients or&#xD;
             progesterone or to any of the excipients of the additional study medications&#xD;
&#xD;
          -  Clinically significant abnormal findings at Visit 1 that, in the opinion of the&#xD;
             investigator, can affect trial resulkts or subject's safety&#xD;
&#xD;
          -  Administration of other investigational products within the previous month or&#xD;
             concomitant participation in another study protocol&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>37 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergio Pasqualini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Halitus Instituto Medico</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Halitus Instituto Médico</name>
      <address>
        <city>Buenos Aires</city>
        <state>Caba</state>
        <zip>C1122AAF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>May 22, 2015</study_first_submitted>
  <study_first_submitted_qc>May 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2015</study_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Assisted reproduction technologies</keyword>
  <keyword>Follicle stimulating hormone (FSH).</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

